1-Boc-6-苄氧基吲哚 | 933474-39-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吲哚及其衍生物
• 中文名称: 1-Boc-6-苄氧基吲哚
• 中文别名: 6-苄氧基-1H-吲哚-1-羧酸叔丁酯
• 英文名称: 6-benzyloxy-indole-1-carboxylic acid tert-butyl ester
• 英文别名: tert-butyl 6-(benzyloxy)-1H-indole-1-carboxylate；6-benzyloxy-1-(tert-butoxycarbonyl)-1H-indole；tert-butyl 6-phenylmethoxyindole-1-carboxylate
• CAS: 933474-39-6
• 化学式: C₂₀H₂₁NO₃
• 分子量: 323.392
• InChiKey: SRPBCFXYURDQFS-UHFFFAOYSA-N

物化性质

• 熔点：
  105 °C
• 沸点：
  460.9±37.0 °C(Predicted)
• 密度：
  1.10±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.7
• 重原子数：
  24
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  40.5
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi
• 海关编码：
  2933990090

SDS

Material Safety Data Sheet

---

Section 1. Identification of the substance
Product Name: 1-BOC-6-benzyloxyindole
Synonyms: tert-Butyl 6-(benzyloxy)-1H-indole-1-carboxylate; tert-Butyl 6-benzyloxyindole-1-carboxylate

---

Section 2. Hazards identification
Harmful by inhalation, in contact with skin, and if swallowed.

---

Section 3. Composition/information on ingredients.
Ingredient name: 1-BOC-6-benzyloxyindole
CAS number: 933474-39-6

---

Section 4. First aid measures
Skin contact: Immediately wash skin with copious amounts of water for at least 15 minutes while removing
contaminated clothing and shoes. If irritation persists, seek medical attention.
Eye contact: Immediately wash skin with copious amounts of water for at least 15 minutes. Assure adequate
flushing of the eyes by separating the eyelids with fingers. If irritation persists, seek medical
attention.
Inhalation: Remove to fresh air. In severe cases or if symptoms persist, seek medical attention.
Ingestion: Wash out mouth with copious amounts of water for at least 15 minutes. Seek medical attention.

---

Section 5. Fire fighting measures
In the event of a fire involving this material, alone or in combination with other materials, use dry
powder or carbon dioxide extinguishers. Protective clothing and self-contained breathing apparatus
should be worn.

---

Section 6. Accidental release measures
Personal precautions: Wear suitable personal protective equipment which performs satisfactorily and meets local/state/national
standards.
Respiratory precaution: Wear approved mask/respirator
Hand precaution: Wear suitable gloves/gauntlets
Skin protection: Wear suitable protective clothing
Eye protection: Wear suitable eye protection
Methods for cleaning up: Mix with sand or similar inert absorbent material, sweep up and keep in a tightly closed container
for disposal. See section 12.
Environmental precautions: Do not allow material to enter drains or water courses.

---

Section 7. Handling and storage
Handling: This product should be handled only by, or under the close supervision of, those properly qualified
in the handling and use of potentially hazardous chemicals, who should take into account the fire,
health and chemical hazard data given on this sheet.
Store in closed vessels.
Storage:

---

Section 8. Exposure Controls / Personal protection
Engineering Controls: Use only in a chemical fume hood.
Personal protective equipment: Wear laboratory clothing, chemical-resistant gloves and safety goggles.
General hydiene measures: Wash thoroughly after handling. Wash contaminated clothing before reuse.

---

Section 9. Physical and chemical properties
Appearance: Not specified
Boiling point: No data
No data
Melting point:
Flash point: No data
Density: No data
Molecular formula: C20H21NO3
Molecular weight: 323.4

---

Section 10. Stability and reactivity
Conditions to avoid: Heat, flames and sparks.
Materials to avoid: Oxidizing agents.
Possible hazardous combustion products: Carbon monoxide, nitrogen oxides.

---

Section 11. Toxicological information
No data.

---

Section 12. Ecological information
No data.

---

Section 13. Disposal consideration
Arrange disposal as special waste, by licensed disposal company, in consultation with local waste
disposal authority, in accordance with national and regional regulations.

---

Section 14. Transportation information
Non-harzardous for air and ground transportation.

---

Section 15. Regulatory information
No chemicals in this material are subject to the reporting requirements of SARA Title III, Section
302, or have known CAS numbers that exceed the threshold reporting levels established by SARA
Title III, Section 313.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-Boc-6-苄氧基吲哚 在 Oxone 、 copper(II) choride dihydrate 、 硼酸三异丙酯 、 palladium on activated charcoal 、 氯化铂 、 三氟乙酸 、 lithium diisopropyl amide 作用下， 以 四氢呋喃 、 1,4-二氧六环 、 正己烷 、 二氯甲烷 、 乙酸乙酯 、 乙腈 为溶剂， 20.0 ℃ 、101.33 kPa 条件下， 反应 220.83h， 生成 7,7-dimethyl-1,7-dihydropyrano[2,3-g]indol-2(3H)-one
  参考文献：
  名称：

  快速获得螺环羟吲哚生物碱：不对称钯催化 [3 + 2] 三亚甲基甲烷环加成的应用

  摘要：

  marcfortines 是复杂的次生代谢物，显示出有效的驱虫活性，其特征是存在与螺吲哚融合的双环 [2.2.2] 二氮杂辛烷。在此，我们报告了该家族的两个成员的合成。marcfortine B 的合成利用羧基 TMM 环加成来建立螺环核心，然后是分子内迈克尔加成和氧化自由基环化以进入应变双环系统。此外，还描述了 (-)-marcfortine C 的首次不对称合成。关键步骤涉及氰基取代的 TMM 环加成，其以几乎定量的收率进行，具有高非对映选择性和对映选择性。所得手性中心用于建立天然产物中所有剩余的立体中心。

  DOI：

  10.1021/ja409013m
• 作为产物：
  描述：

  6-苄氧基吲哚 、 二碳酸二叔丁酯 在 4-二甲氨基吡啶 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以99%的产率得到1-Boc-6-苄氧基吲哚
  参考文献：
  名称：

  Selective NR1/2B N-Methyl-d-aspartate Receptor Antagonists among Indole-2-carboxamides and Benzimidazole-2-carboxamides

  摘要：

  (4-苄基哌啶-1-基)-(6-羟基-1H-吲哚-2-基)-甲酮(6a)是从(E)-1-(4-苄基哌啶-1-基)-3-(4-羟基苯基)丙烯酮(5)中鉴定出的一种强效的NMDA受体NR2B亚基选择性拮抗剂。为了建立结构-活性关系(SAR)并尝试改善先导化合物的ADME性质，制备并测试了一系列化合物。多种衍生物在结合和功能性测定中均显示出低纳摩尔的活性。在环磷酰胺诱导的小鼠痛觉过敏模型中，6a和(4-苄基哌啶-1-基)-[5(6)-羟基-1H-联吡啶-2-基]-甲酮(60a)在口服给药后与Besonprodil(2)具有相同的活性。基于一系列吲哚-和联吡啶-2-羧酰胺的结合数据，开发了一种CoMSIA模型。

  DOI：

  10.1021/jm060420k

文献信息

• Indolyne Experimental and Computational Studies: Synthetic Applications and Origins of Selectivities of Nucleophilic Additions
  作者：G-Yoon J. Im、Sarah M. Bronner、Adam E. Goetz、Robert S. Paton、Paul H.-Y. Cheong、K. N. Houk、Neil K. Garg

  DOI：10.1021/ja1086485

  日期：2010.12.22

  conditions, trapped by a variety of nucleophilic reagents, and used to access a number of novel substituted indoles. Nucleophilic addition reactions to indolynes proceed with varying degrees of regioselectivity; distortion energies control regioselectivity and provide a simple model to predict the regioselectivity in the nucleophilic additions to indolynes and other unsymmetrical arynes. This model

  4,5-、5,6- 和 6,7-吲哚炔前体的有效合成从商业上可获得的羟基吲哚衍生物开始已有报道。合成路线是通用的，并允许获得在吡咯环上保持未取代的吲哚炔前体。Indolynes 可以在温和的氟化物介导的条件下生成，被各种亲核试剂捕获，并用于获取许多新型取代的吲哚。吲哚的亲核加成反应具有不同程度的区域选择性；畸变能控制区域选择性，并提供一个简单的模型来预测吲哚和其他不对称芳烃的亲核加成中的区域选择性。该模型导致设计出具有增强的亲核区域选择性的取代 4,5-吲哚炔。
• Concise syntheses of the 1,7-dihydropyrano[2,3-g]indole ring system of the stephacidins, aspergamides and norgeamides
  作者：Alan W. Grubbs、Gerald D. Artman、Robert M. Williams

  DOI：10.1016/j.tetlet.2005.10.112

  日期：2005.12

  towards the synthesis of the 1,7-dihydropyrano[2,3-g]indole ring system of the stephacidins, paraherquamides and norgeamides have been investigated. The first involves a tandem nitrene insertion/aromatic Claisen rearrangement. The second consists of a more conventional approach from commercially available 6-benzyloxyindole. The third approach is a revised synthesis of the 2-prenylated pyrano indole necessary

  已经研究了三种合成Stephacidins，对乙酰氨基甲酰胺和降冰酰胺的1,7-二氢吡喃并[2,3- g ]吲哚环系统的方法。第一个涉及串联的氮烯插入/芳族克莱森重排。第二种是由可商购的6-苄氧基吲哚得到的更常规的方法。第三种方法是对仿生的狄尔斯-阿尔德方法进行仿生的狄斯卡德-阿德耳方法的合成合成，其中所述方法是对步冬青素，天冬酰胺和降冰片酰胺的仿生。
• Selective NR1/2B <i>N</i>-Methyl-<scp>d</scp>-aspartate Receptor Antagonists among Indole-2-carboxamides and Benzimidazole-2-carboxamides
  作者：István Borza、Éva Bozó、Gizella Barta-Szalai、Csilla Kiss、Gábor Tárkányi、Ádám Demeter、Tamás Gáti、Viktor Háda、Sándor Kolok、Anikó Gere、László Fodor、József Nagy、Kornél Galgóczy、Ildikó Magdó、Béla Ágai、József Fetter、Ferenc Bertha、György M. Keserü、Csilla Horváth、Sándor Farkas、István Greiner、György Domány

  DOI：10.1021/jm060420k

  日期：2007.3.1

  (4-Benzylpiperidine-1-yl)-(6-hydroxy-1H-indole-2-yl)-methanone (6a) derived from (E)-1-(4-benzylpiperidin-1-yl)-3-(4-hydroxy-phenyl)-propenone (5) was identified as a potent NR2B subunit-selective antagonist of the NMDA receptor. To establish the structure-activity relationship (SAR) and to attempt the improvement of the ADME properties of the lead, a series of compounds were prepared and tested. Several derivatives showed low nanomolar activity both in the binding and in the functional assay. In a formalin-induced hyperalgesia model in mice, 6a and (4-benzylpiperidine-1-yl)-[5(6)-hydroxy-1H-benzimidazol-2-yl]-methanone (60a) were as active as besonprodil (2) after oral administration. A CoMSIA model was developed based on binding data of a series of indole- and benzimidazole-2-carboxamides.

  (4-苄基哌啶-1-基)-(6-羟基-1H-吲哚-2-基)-甲酮(6a)是从(E)-1-(4-苄基哌啶-1-基)-3-(4-羟基苯基)丙烯酮(5)中鉴定出的一种强效的NMDA受体NR2B亚基选择性拮抗剂。为了建立结构-活性关系(SAR)并尝试改善先导化合物的ADME性质，制备并测试了一系列化合物。多种衍生物在结合和功能性测定中均显示出低纳摩尔的活性。在环磷酰胺诱导的小鼠痛觉过敏模型中，6a和(4-苄基哌啶-1-基)-[5(6)-羟基-1H-联吡啶-2-基]-甲酮(60a)在口服给药后与Besonprodil(2)具有相同的活性。基于一系列吲哚-和联吡啶-2-羧酰胺的结合数据，开发了一种CoMSIA模型。
• Concise, Asymmetric, Stereocontrolled Total Synthesis of Stephacidins A, B and Notoamide B
  作者：Gerald D. Artman、Alan W. Grubbs、Robert M. Williams

  DOI：10.1021/ja070259i

  日期：2007.5.1

  Concise asymmetric total syntheses of the fungal metabolites (-)-stephacidin A, (+)-stephacidin B, and (+)-notoamide B are described. Key features of these total syntheses include (1) a facile synthesis of (R)-allyl proline methyl ester, (2) a revised route toward the pyranoindole ring system, (3) a novel cross-metathesis strategy for the introduction of important functional groups, and (4) an SN2'

  描述了真菌代谢物 (-)-stephacidin A、(+)-stephacidin B 和 (+)-notoamide B 的简洁不对称全合成。这些全合成的关键特征包括（1）（R）-烯丙基脯氨酸甲酯的简便合成，（2）吡喃吲哚环系统的修正路线，（3）引入重要功能的新型交叉复分解策略基团，和（4）SN2'环化形成[2.2.2]桥连双环系统。此外，我们的合成利用微波加热来缩短反应时间并提高重要中间体制备的产率。
• HETEROARYLAMIDE LOWER CARBOXYLIC ACID DERIVATIVE
  申请人：Machinaga Nobuo

  公开号：US20090324581A1

  公开（公告）日：2009-12-31

  To provide a novel compound which has S1P receptor agonistic activity, exhibits excellent immunosuppressing effect, gives less adverse side effects, and can be orally administered. The invention provides a compound represented by general formula (I) (wherein A is a single bond, —O—, or —CH 2 —; R 1 represents a hydrogen atom or a C 1 -C 6 alkyl group, and V represents any one group selected from among the following groups (1) to (3): (1) -G 1 -, (2) -G 2 -N(R 2 )-G 3 -, and (3) a group represented by formula 2, wherein each of Z 1 and Z 2 represents a hydrogen atom or a C 1 -C 6 alkyl group, Z 3 represents a hydrogen or the like, Q represents —CH 2 —O— or the like, and Y represents a group represented by formula 3, a salt thereof, or a solvate thereof.

  提供一种新型化合物，具有S1P受体激动活性，表现出优异的免疫抑制效果，产生较少的不良副作用，并可口服。本发明提供一种由通式（I）表示的化合物（其中A是单键，-O-或-CH2-；R1表示氢原子或C1-C6烷基基团，V表示从以下组（1）至（3）中选择的任一组：（1）-G1-，（2）-G2-N（R2）-G3-，以及（3）由式2表示的组，其中Z1和Z2分别表示氢原子或C1-C6烷基基团，Z3表示氢或类似物，Q表示-CH2-O-或类似物，Y表示由式3表示的基团，其盐或溶剂化物。